H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target
H.C. Wainwright isn’t backing off Summit Therapeutics (NASDAQ: SMMT).
Summit Therapeutics Inc. (SMMT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lansdowne Partners Alex Snow | 0 | $0 | 0% | |
| 2. | Renaissance Technologies Jim Simons | 0 | $0 | 0% | |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.71 | 20,000 | $74,200.00 | 50,000 | 2024-03-27 | Filing | |
| $3.75 | 30,000 | $112,500.00 | 30,000 | 2024-03-26 | Filing | |
| $3.72 | 34,321 | $127,674.12 | 24,923,800 | 2024-03-27 | Filing | |
| $3.72 | 26,000 | $96,720.00 | 520,814 | 2024-03-27 | Filing | |
| $3.75 | 100,000 | $375,000.00 | 354,958 | 2024-03-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.44 | 13,713 | $60,885.72 | 0 | 2020-11-30 | Filing | |
| $4.39 | 29,569 | $129,807.91 | 0 | 2020-11-27 | Filing | |
| $4.32 | 12,070 | $52,142.40 | 0 | 2020-11-25 | Filing | |
| $4.21 | 11,374 | $47,884.54 | 0 | 2020-11-24 | Filing | |
| $4.40 | 6,987 | $30,742.80 | 0 | 2020-11-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 843 | $16,261 | 0% | |
| 2. | 654 | $12,295 | 0% | |
| 3. | 453 | $8,738 | 0% | |
| 4. | 195 | $3,762 | 0% | |
| 5. | 70 | $1,350 | 0% |
News See All
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday
We recently published a list of Investors Are Dumping These 10 Stocks.
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday
We recently published a list of 10 Stocks Leaving Wall Street in The Dust.
Truist Sticks to $35 Target on Summit (SMMT) Despite Shifting Deal Landscape
In a June 2 report, Truist Securities analyst Asthika Goonewardene weighed in on the implications of Bristol-Myers Squibb’s newly announced partnership with BioNTech SE on Summit Therapeutics Inc.
Why Summit Therapeutics Inc. (SMMT) Crashed Last Week
We recently published a list of These 10 Stocks Just Rocked The Market. In this article, we are going to take a look at where Summit Therapeutics Inc.
Why Summit Therapeutics Inc. (SMMT) Crashed On Friday
We recently published a list of These 10 Stocks Lost This Much Today.
Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal
Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc.
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. Hello and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call.
12 Best Multibagger Stocks to Buy in 2025
In the world of investing, the term "multibagger" refers to stocks that have the potential to deliver returns several times greater than the original investment.